<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Deloitte</title>
	<atom:link href="http://www.tapanray.in/tag/deloitte/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Pharma R&amp;D: Chasing A Rainbow To Replicate The Past</title>
		<link>http://www.tapanray.in/pharma-rd-chasing-a-rainbow-to-replicate-the-past/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-rd-chasing-a-rainbow-to-replicate-the-past</link>
		<comments>http://www.tapanray.in/pharma-rd-chasing-a-rainbow-to-replicate-the-past/#comments</comments>
		<pubDate>Mon, 25 Jan 2016 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Deloitte]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[Disruptive]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[eclectic]]></category>
		<category><![CDATA[exorbitant]]></category>
		<category><![CDATA[external]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Harmoni]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Nucala]]></category>
		<category><![CDATA[past]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rainbow]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[replicate]]></category>
		<category><![CDATA[return]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Treshba]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7405</guid>
		<description><![CDATA[Would future be always a replica of the past? If the response is yes, the efforts of many global pharma players to replicate the successful Research and Development (R&#38;D) models of long gone by days, would continue to be a &#8230; <a href="http://www.tapanray.in/pharma-rd-chasing-a-rainbow-to-replicate-the-past/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-rd-chasing-a-rainbow-to-replicate-the-past/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Paying For The Best Health Outcomes At The Lowest Possible Cost</title>
		<link>http://www.tapanray.in/paying-for-the-best-health-outcomes-at-the-lowest-possible-cost/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=paying-for-the-best-health-outcomes-at-the-lowest-possible-cost</link>
		<comments>http://www.tapanray.in/paying-for-the-best-health-outcomes-at-the-lowest-possible-cost/#comments</comments>
		<pubDate>Mon, 08 Dec 2014 00:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[best]]></category>
		<category><![CDATA[Burrill]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Dekkers]]></category>
		<category><![CDATA[Deloitte]]></category>
		<category><![CDATA[Gallup]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[ICER]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Levitra (vardenafil)]]></category>
		<category><![CDATA[Marijn]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Michael Porter]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[OBP]]></category>
		<category><![CDATA[Outcomes. Lowest]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[QALY]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[STG]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thomas Lee]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[VBP]]></category>
		<category><![CDATA[Velcade (bortezomib)]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6244</guid>
		<description><![CDATA[“Bayer CEO Dr. Marijn Dekkers is happy to have fair Outcomes-Based Pricing”, reported ‘PharmaTimes’ on December 3, 2014. Dr. Dekkers was quoted saying, “It is okay to be tested on that in the process of price-setting, that is fine, we should &#8230; <a href="http://www.tapanray.in/paying-for-the-best-health-outcomes-at-the-lowest-possible-cost/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/paying-for-the-best-health-outcomes-at-the-lowest-possible-cost/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The R&amp;D Factor: “One of the Great Myths of the Industry&#8221;</title>
		<link>http://www.tapanray.in/the-rd-factor-one-of-the-great-myths-of-the-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-rd-factor-one-of-the-great-myths-of-the-industry</link>
		<comments>http://www.tapanray.in/the-rd-factor-one-of-the-great-myths-of-the-industry/#comments</comments>
		<pubDate>Mon, 25 Mar 2013 00:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[1 billion]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[android]]></category>
		<category><![CDATA[Deloitte]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[economics]]></category>
		<category><![CDATA[factor]]></category>
		<category><![CDATA[Frost]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[global. CEO]]></category>
		<category><![CDATA[greatest]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[London]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[myths]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[one]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OS]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reuters]]></category>
		<category><![CDATA[School]]></category>
		<category><![CDATA[sequencing]]></category>
		<category><![CDATA[Sullivan]]></category>
		<category><![CDATA[sustainability]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[Thomson]]></category>
		<category><![CDATA[Tuft]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[vindication]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2085</guid>
		<description><![CDATA[Yes, that is what the global CEO of one of the Pharmaceutical giants of the world commented in a very recent interview with Reuters. Adding further to this comment he said, “US $1 billion price tag for R&#38;D was an &#8230; <a href="http://www.tapanray.in/the-rd-factor-one-of-the-great-myths-of-the-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-rd-factor-one-of-the-great-myths-of-the-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
